肝硬化并发自发性细菌性腹膜炎临床研究进展*

doi:10.3969/j.issn.1672-5069.2022.06.038

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (6): 909-912.doi: 10.3969/j.issn.1672-5069.2022.06.038

• 综述 • 上一篇

肝硬化并发自发性细菌性腹膜炎临床研究进展^*

沈一芃综述, 祝峻峰审校

200071 上海市上海中医药大学附属中医医院感染性疾病科(沈一芃);上海中医药大学附属岳阳中西医结合医院肝病科(祝峻峰)

收稿日期:2022-01-26 出版日期:2022-11-10 发布日期:2022-11-22
通讯作者: 祝峻峰,E-mail:zhujftongling@163.com
作者简介:沈一芃,女,29岁,硕士研究生,住院医师。E-mail:SHENyipeng1991@163.com
基金资助:
^*国家自然科学基金资助项目(编号:82074386);上海申康医院发展中心临床三年行动计划资助项目(编号: SHDC2020CR3095B)

Spontaneous bacterial peritonitis in patients with liver cirrhosis

Shen Yipeng, Zhu Junfeng

Department of Infectious Diseases,Shanghai Municipal Hospital of Traditional Chinese Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200071,China

Received:2022-01-26 Online:2022-11-10 Published:2022-11-22

摘要/Abstract

摘要： 目的自发性细菌性腹膜炎(SBP)为目前肝硬化患者最常见的并发症之一,具有发病率高,疾病发展快,病死率高等特征。该病临床表现常不典型,腹腔感染的诊断主要基于腹腔积液白细胞计数。治疗则以经验性抗生素使用为主,联合调节肠道菌群、补充白蛋白等。有条件者可考虑肝移植。早期发现并积极实施干预对改善本病预后、降低病死率都有着重要的意义,但在有关SBP诊断、治疗和预防方面,仍面临巨大的挑战,需要深入研究进一步解决相关问题的策略,从而更好地指导临床实践,改善患者预后。

关键词: 肝硬化, 自发性细菌性腹膜炎, 诊断, 治疗

Abstract: Objective The spontaneous bacterial peritonitis (SBP) is one of the most common complications in patients with cirrhosis, with high clinical incidence, rapid disease development and high mortality. The clinical manifestations of SBP are often not very typical, and the diagnosis of celiac infection is mainly based on the white blood cell counts in celiac fluid. The treatment is mainly empirical antibiotic administration and intestinal flora modulation. Early diagnosis and active intervention are of great importance to improve the prognosis and reduce the mortality, but there are still some great challenges in the diagnosis, treatment and prevention of the entity, which require in-depth study to further solve the relevant problems, so as to guide the clinical practice and improve the patient's prognosis.

Key words: Liver cirrhosis, Spontaneous bacterial peritonitis, Diagnosis, Treatment

沈一芃, 祝峻峰. 肝硬化并发自发性细菌性腹膜炎临床研究进展^*[J]. 实用肝脏病杂志, 2022, 25(6): 909-912.

Shen Yipeng, Zhu Junfeng. Spontaneous bacterial peritonitis in patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2022, 25(6): 909-912.

参考文献

[1] Mokdad AA,Lopez AD,Shahraz S,et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med,2014,12(1):145.
[2] Wang X,Lin SX,Tao J,et al. Study of liver cirrhosis over ten consecutive years in Southern China.World J Gastroenterol,2014,20(37):13546-13555.
[3] Bao X, Xu B, Fang K, et al. Changing trends of hospitalisation of liver cirrhosis in Beijing, China. BMJ Open Gastroenterol,2015,2(1): e000051.
[4] Conn HO. Spontaneous peritonitis and bacteremia in Laennecfs cirrhosis caused by enteric organisms:A relatively common but rarely recognized syndrome. Ann Intern Med,1964,60:568-580.
[5] Soriano G,Castellote J,Alvarez C,et al. Secondary bacterial peritonitis in cirrhosis: A retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol, 2010, 52(1) : 39-44.
[6] Arvaniti V, Damico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology,2010,139(4):1246-56.
[7] Alexopoulou A,Vasilieva L, Agiasotelli D,et al. Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. World J Gastroenterol,2016,22(15):4049-4056.
[8] Wang Z,Sun R,Wang G,et al.SIRT3-mediated deacetylation of PRDX3 alleviates mitochondrial oxidative damage and apoptosis induced by intestinal ischemia/reperfusion injury.Redox Biol,2020,28:101343.
[9] Liu X,Liang F,Song W,et al.Effect of Nrf2 signaling pathway on the improvement of intestinal epithelial barrier dysfunction by hyperbaric oxygen treatment after spinal cord injury.Cell Stress Chaperones,2021,26(2):433-441.
[10] Cahenzli J,Koller Y,Wyss M,et al. Intestinal microbial diversity during early-life colonization shapes long-term IgE levels.Cell Host Microbe,2013,14( 5) : 559-570.
[11] Tanouev T,Morita S,Plichta DR,et al.A defined commensal con- sortium elicits CD8 T cells and anti-cancer immunity.Nature,2019,565(7741):600-605.
[12] Liu X,Chen Y,You B,et al.Molecular mechanism mediating enteric bacterial translocation after severe burn:The role of cystic fibrosis transmembrane conductance regulator.Burns Trauma,2021,8:42.
[13] 梅毅,张茹,彭贺新,等.肝硬化合并自发性细菌性腹膜炎患者免疫因子Th17/Treg失衡的作用机制研究.血栓与止血学,2015,21(5):307-309.
[14] Campbell KA,Trivedi HD,Chopra S. Infections in cirrhosis: a guide for the clinician. Am J Med, 2021, 134(6) : 727-734.
[15] 高方博,白朝辉,林苏,等. 《2020年英国胃肠病学会与英国肝病学会指南:肝硬化腹水管理》摘译.临床肝胆病杂志,2021,37(2):302-303.
[16]中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21(1):21-31.
[17] 彭官清,凌乔,潘沛沛,等.肝硬化并发自发性细菌性腹膜炎患者血清中颗粒蛋白前体水平及临床意义.中华医院感染学杂志,2019,29(23):3558-3562.
[18] 李杰,张莉. sTREM-1含量、血降钙素原和C-反应蛋白在肝硬化腹水非多形核细胞性自发性细菌性腹膜炎的诊断意义.中国中西医结合消化杂志,2019,27(6):456-460.
[19] Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology,2016,63(4):1299-309.
[20] Merli M, Lucidi C, Di GV, et al. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial. Hepatology,2016,63(5):1632-1639.
[21] Qin N,Yang F,Li A,et al. Alterations of the human gut microbiome in liver cirrhosis. Nature,2014,513( 7516) :59-64.
[22] Alexopoulou A, Agiasotelli D, Vasilieva LE, et al. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol,2017,30(5):486-497.
[23] Wong CB, Sugahara H, Odamaki T, et al. Different physiological properties of human-residential and non-human-residential bifidobacteria in human health. Benef Microbes,2018,29;9(1):111-122.
[24] 梁栋,边绪强,张鼎.腹腔置管灌洗联合腹腔注射抗生素治疗肝硬化自发性腹膜炎的临床研究.肝脏,2021,26(1):37-40.
[25] Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol,2013,11(2):123-30.
[26] 张囡囡,徐雷,刘鹏.参苓白术颗粒对自发性腹膜炎的治疗作用.中国中医急症,2015,24(12):2252-2254.
[27] Fernandez J, Tandon P, Mensa J, et al. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology,2016,63(6): 2019-2031.
[28] Elfert A, Abo AL, Soliman S, et al. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol,2016,28(12):1450-1454.
[29] Gong ZY, Yuan ZQ, Dong ZW, et al. Glutamine with probiotics attenuates intestinal inflammation and oxidative stress in a rat burn injury model through altered iNOS gene aberrant methylation. Am J Transl Res,2017,9(5):2535-2547.

肝硬化并发自发性细菌性腹膜炎临床研究进展^*

Spontaneous bacterial peritonitis in patients with liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩涛, 刘艳迪, 胡家轩. 肝病合并肾损伤临床诊治新进展[J]. 实用肝脏病杂志, 2022, 25(6): 761-763.
[2]	蒋莹莹, 丁惠国. 肝硬化并发急性肾损伤临床管理现状与挑战[J]. 实用肝脏病杂志, 2022, 25(6): 764-767.
[3]	韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.
[4]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[5]	吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁. 血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 780-783.
[6]	许海玲, 秦刚, 薛红, 章颖. 艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 788-791.
[7]	赵资德, 吴令杰, 张海生, 陈瑞烈. 纠正低蛋白血症减少抗结核药物性肝损伤发生临床研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 792-795.
[8]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[9]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[10]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[11]	王玉梅, 袁向东, 刘玉玲, 赵子瑜. 提示肥胖症儿童/青少年存在非酒精性脂肪性肝炎的指标分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 808-811.
[12]	贺锦帆, 姚佳, 赵强, 王娟, 白津佳, 赵凝慧. 双重血浆分子吸附系统治疗肝衰竭患者发生血管迷走神经反应相关因素分析及其处理对策研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 828-831.
[13]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[14]	徐超, 李兰, 罗东, 赵海云, 彭飞. TIPS术治疗的肝硬化并发EVB患者医院内死亡风险预测模型的构建与应用^*[J]. 实用肝脏病杂志, 2022, 25(6): 840-843.
[15]	林秀慧, 李南, 张娇珍, 符庆忠, 林秀华. 慢性HBV感染者外周血PNPLA3/PRKAA1基因多态性与肝硬化发生关系研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 844-847.